Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) EBITDA: 2018-2024

Historic EBITDA for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to -$599.3 million.

  • Revolution Medicines' EBITDA fell 101.44% to -$303.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 65.38%. This contributed to the annual value of -$599.3 million for FY2024, which is 38.08% down from last year.
  • Per Revolution Medicines' latest filing, its EBITDA stood at -$599.3 million for FY2024, which was down 38.08% from -$434.0 million recorded in FY2023.
  • Revolution Medicines' 5-year EBITDA high stood at -$110.7 million for FY2020, and its period low was -$599.3 million during FY2024.
  • In the last 3 years, Revolution Medicines' EBITDA had a median value of -$434.0 million in 2023 and averaged -$427.8 million.
  • Data for Revolution Medicines' EBITDA shows a maximum YoY slumped of 104.54% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Revolution Medicines' EBITDA stood at -$110.7 million in 2020, then plummeted by 69.46% to -$187.6 million in 2021, then tumbled by 33.33% to -$250.1 million in 2022, then tumbled by 73.54% to -$434.0 million in 2023, then slumped by 38.08% to -$599.3 million in 2024.